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To gain insights into the regulatory mechanisms of
hematopoietic stem cells (HSCs), we employed a
genome-wide RNAi screen in human cord-blood
derived cells and identified candidate genes whose
knockdown maintained the HSC phenotype during
culture. A striking finding was the identification of
members of the cohesin complex (STAG2, RAD21,
STAG1, and SMC3) among the top 20 genes from
the screen. Upon individual validation of these cohe-
sin genes, we found that their knockdown led to an
immediate expansion of cells with anHSCphenotype
in vitro. A similar expansion was observed in vivo
following transplantation to immunodeficient mice.
Transcriptome analysis of cohesin-deficient CD34+
cells showed an upregulation of HSC-specific genes,
demonstrating an immediate shift toward a more
stem-cell-like gene expression signature upon cohe-
sin deficiency. Our findings implicate cohesin as a
major regulator of HSCs and illustrate the power of
global RNAi screens to identify modifiers of cell fate.
INTRODUCTION
Human hematopoiesis is maintained by a small number of he-
matopoietic stem cells (HSCs) that are capable of generating
all blood cell lineages at an extremely rapid pace for the entire
lifespan of a human being (Orkin and Zon, 2008). HSCs have
been studied extensively during the last four decades and are
probably the best functionally characterized adult stem cells.
However, despite this, the regulatory mechanisms that govern
different cellular fate options in HSCs have remained incom-
pletely defined. In particular, it has been challenging to under-
stand the molecular basis of the inherent ability of HSCs to
self-renew and preserve their undifferentiated state, which has
hampered efforts to expand HSCs ex vivo for therapeutic benefit
(Dahlberg et al., 2011). Ex vivo expansion of HSCs would allow2988 Cell Reports 14, 2988–3000, March 29, 2016 ª2016 The Authorfor critical improvements of bone marrow transplantation proce-
dures in treatment of malignant and inherited hematological
diseases (Chou et al., 2010). Defining the genetic and molecular
basis of self-renewal of HSCs is thus important to enhance cur-
rent cell-therapy strategies, but it is also essential in order to bet-
ter understandmechanisms behind dysregulated hematopoiesis
that may cause leukemia. Genes and pathways balancing cell-
fate options between renewal and differentiation in stem cells
are often key players in cancer development (Orkin and Zon,
2008).
Traditionally, assessment of gene function in mammals has
been based on reverse genetic approaches in which individual
candidate genes are studied. However, the development of
RNAi technology about a decade ago has transformed functional
genetics and provided tools to perform forward genetic screens
in primary mammalian cells (Hannon and Rossi, 2004). RNAi
screening has emerged as a powerful tool to genetically dissect
functional aspects of both normal and malignant HSCs using
short hairpin RNA (shRNA) retroviral and lentiviral vector-libraries
(Karlsson et al., 2014). Recent studies have identified fate deter-
minants in murine HSCs through focused screens targeting
histone modifiers (Cellot et al., 2013), polycomb repressor com-
plex (PRC) genes (Kinkel et al., 2015), and regulators of polarity
and asymmetric cell division (Hope et al., 2010). RNAi screens
have also successfully identified several important driver genes
in malignant hematopoiesis, most notably in acute myeloid leu-
kemia, both in vitro (Zuber et al., 2011) and in vivo (Miller et al.,
2013). These studies have also been performed in murine set-
tings using pre-selected libraries targeting specific gene cate-
gories or families.
Our laboratory has developed paradigms to perform forward
RNAi screens in primary human hematopoietic stem and pro-
genitor cells (HSPCs), using pooled lentiviral shRNA libraries
(Ali et al., 2009; Baudet et al., 2012). From a screen targeting
mainly kinases and phosphatases, we reported the identification
of MAPK14 (p38) as a druggable modifier of expansion of umbil-
ical cord blood (CB)-derived HSPCs, supporting the feasibility of
RNAi screens as a tool for gene discovery in primary human he-
matopoietic cells (Baudet et al., 2012). However, these previous
screens have been limited to around 1,000 genes and have nots
directly assessed stem cell properties. Here, we now report on
the development of a two-step screening paradigm to address
these limitations. We first targeted a near genome-wide lentiviral
shRNA library to human CB-derived CD34+ cells to globally
define genes restricting expansion of HSPCs. The highest
ranked genes were subsequently subjected to a secondary
screen in highly purified HSCs to filter out stem-cell-specific out-
comes related to self-renewal and differentiation. From this
approach, we have discovered putative regulators of cell fate
in HSCs and specifically identified several components of the
cohesin complex as critical regulators of HSC renewal and differ-
entiation both in vitro and in vivo.
RESULTS
Genome-wide RNAi Screen in Primitive Human
Hematopoietic Cells Defines Genes and Pathways
Associated with Cell Expansion and Cancer
Development
In order to globally search for modifiers of HSC renewal and dif-
ferentiation, we performed a near genome-wide, pooled lentiviral
shRNA screen in primary human CB-derived CD34+ cells. As a
basis for the screen, we used the limited persistence of the
immature cell phenotype (CD34+) under ex vivo culture condi-
tions, selecting for shRNAs conferring increased expansion of
stem and progenitor cells. We have previously shown using
smaller libraries that this approach enables the identification of
genes and pathways that influence renewal and differentiation
of HSCs (Ali et al., 2009; Baudet et al., 2012).
We used a lentiviral library consisting of 75,000 shRNA vectors
targeting 15,000 genes developed by the RNAi Consortium
(TRC) at the Broad Institute and distributed as pooled lentiviral
particles by Sigma Aldrich (Figure S1A). To ensure optimal repre-
sentation of the highly complex library in the screen, we collected
CD34+ cells from more than 100 CB units. A total of 60 million
CD34+ cells were subsequently transduced with the library in
six replicate screens (Figure 1A). To avoid multiple shRNA inte-
grations in a single cell, we aimed to keep the transduction effi-
ciency below 37% and validated this by clonal PCR analysis of
vector integration in hematopoietic colonies from transduced
the cells (Figure S1B). On average, the transduction efficiency
was 30%.
Following transduction, the cells were cultured for 20 days in
serum-free medium supplemented with growth factors. We as-
sessed the distribution of all shRNAs in the library by next-gen-
eration sequencing of integrated proviruses amplified from
genomic DNA of CD34+ cells, 3 days after transduction and
following 20 days of culture (Figure 1A). The change in the rela-
tive contribution the shRNAs over timewas used to identify those
influencing the expansion of CD34+ cells. We thus determined
the ratios between the normalized counts for all shRNAs be-
tween day 20 and day 3 and plotted them from themost enriched
to the most depleted (Figure 1B). Out of the 75,000 shRNAs
included in the library, we could readily detect 68,000 (91%) at
both time points; the remaining shRNA were excluded from
further analysis. The overall coverage of the library in the screen
was consequently estimated to be 300X (i.e., each shRNA was
targeted to on average 300 cells). As CD34+ cells represent aCellrelatively heterogeneous population of stem and progenitor
cells, we reasoned that this level of coverage would be best
suited for identification of phenotypes detected by positive se-
lection through enrichment of shRNAs, rather than depletion
phenotypes which typically require higher coverage and more
uniform cells with coordinated behavior for accurate detection.
Moreover, as depletion events in RNAi screens are more likely
to be influenced by confounding effects from off-target activity
on essential genes or general toxicity of certain shRNAs, we first
focused our analysis on the enriched fractions of shRNAs and
thus the identification of genes restricting HSPC expansion in
the screening assay.
To test broadly whether the screen had selected for relevant
outcomes with respect to cell expansion, we first performed a
global analysis of all genes targeted by two or more shRNAs
within the 10% most enriched fraction (Figure 1B). Gene
ontology (GO) analysis of the resultant 1,023 genes (Table S1)
showed, in line with our expectations, that the most enriched
gene category was one for genes associated with negative regu-
lation of cell proliferation (Figure 1C). Moreover, KEGG pathway
analysis showed a strong enrichment for several cancer-associ-
ated genes and pathways (Figure 1D). Taken together, this illus-
trates a strong propensity of the unbiased near genome-wide
screen to identify genes inhibiting cell proliferation, as well as
genes involved in cancer development, and validates, in general
terms, the feasibility of our approach as a tool to globally define
genes that modify cell expansion in human HSPCs.
A Secondary Screen Targeted to
CD34+CD38CD90+CD45RA Cells Identifies the
Cohesin Complex as a Candidate Regulator of HSC
Renewal and Differentiation
Our genome-wide screen in CD34+ cells had identified a large
number of candidate genes as potential negative regulators of
cell expansion. However, this first selection of genes was
based on a relatively loose definition (two shRNAs among the
10% most enriched) and could be significantly influenced by
noise from, e.g., random off-target activity from certain
shRNAs. Moreover, CD34 marks a broad repertoire of both
stem cells and progenitor cells and our primary screening
assay did not distinguish between general effects on prolifera-
tion and an actual impact on stem cell self-renewal. Therefore,
in order to further prioritize among the candidate genes and to
filter out the most significant hits with a functional impact on
bona fide HSCs, we decided to apply strict criteria to rank
the genes and then to perform a secondary screen for the high-
est ranked genes in purified HSC populations using a more pre-
cise readout for stem cell activity.
To rank the genes, we first assigned a stringent value to each
shRNA based on the level of enrichment and, when applicable,
the documented knockdown efficiency (data available from
Sigma Aldrich for approximately 50% of all shRNAs). A score
was then calculated for each gene based on the accumulated
values of the corresponding shRNAs and to what extent the
genewas expressed in immature hematopoietic cells (for details,
see the Supplemental Experimental Procedures). The final
ranking based on this score for the top 1,000 genes is shown
in Figure 2A, and the genes are listed in Table S2. The 150Reports 14, 2988–3000, March 29, 2016 ª2016 The Authors 2989
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Figure 1. Genome-wide RNAi Screen in Primitive Human Hematopoietic Cells Defines Genes and Pathways Associated with Cancer
Progression and Cell Proliferation
(A) Overview of the experimental outline for the primary screen. 60 million cord blood-derived CD34+ cells were transduced with a pooled lentiviral library
containing 75,000 shRNAs across six transduction replicates in total. A fraction of the cells were isolated after 72 hr, and proviral inserts were deep sequenced to
determine the initial library distribution. Following 20 days of culture, CD34+ cells were magnetically isolated and proviral inserts were sequenced again to
determine the changes in distribution for all shRNAs.
(B) Relative distribution of shRNAs following 20 days of in vitro culture, ranked from the most enriched to the most depleted. The y axis shows the average
enrichment value across six replicate screens.
(C) Gene ontology analysis for all genes represented by multiple shRNAs in the most enriched (10%) fraction.
(D) KEGG pathway analysis showing strong enrichment for cancer-associated pathways among the top-scoring genes.
See also Figure S1 and Table S1.highest scoring genes were subsequently selected for the sec-
ondary screen and are marked in red in Figure 2A.
Next, we created a pooled shRNA library consisting of a total
of 350 shRNAs against the 150 selected candidate genes. With
this smaller library, we reasoned that it would be feasible to
perform a robust screen in the discrete population of
CD34+CD38CD90+CD45RA cells that is highly enriched in
bona fide HSCs (Majeti et al., 2007). When cultured ex vivo,
the CD34+CD38CD90+CD45RA cells show a strong propen-
sity to differentiate and give rise to three distinct populations
based on expression of CD34 and CD90 after several days;2990 Cell Reports 14, 2988–3000, March 29, 2016 ª2016 The AuthorCD34+CD90+, CD34+CD90, and CD34CD90. We have
recently demonstrated that the in vivo long-term repopulation
potential in such cultures is exclusively contained within the
double-positive CD34+CD90+ cells, while the vast majority of
committed progenitor cells are found in the CD34+CD90 popu-
lation (A.B. and J.L., unpublished data). Tracking of the
CD34+CD90+ population is therefore a sensitive and specific
tool to predict stem cell activity in cultured hematopoietic cells
and provides an excellent basis for a screen aimed at detecting
outcomes influencing self-renewal and differentiation of func-
tional HSCs.s
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For the secondary screen, we sorted CD34+CD38
CD90+CD45RA cells from a total of 50 CB units and transduced
with the pooled shRNA library (with a final coverage of on
average 200 cells per shRNA). Following 10 days of in vitro cul-
ture, we sorted out the three distinct populations based on
CD34 and CD90 expression (Figure 2B). The distribution of all
shRNAs within these three populations was analyzed by deep
sequencing of proviral inserts as described above. Comparison
of the normalized sequencing counts between these three pop-
ulations gave us the opportunity to determine how cells targeted
by a given shRNA had been distributed between the three pop-
ulations (Figure 2C). For all shRNAs in the library we could thus
determine their influence on renewal and differentiation, inde-
pendent of any effects on cell proliferation. Based on this, we
ranked all shRNAs according to their ability to maintain the
CD34+CD90+ population and defined the top-scoring genes as
those having the highest enrichment of CD34+CD90+ cells
across their corresponding shRNAs (Figure 2D; Table S3).
The most notable finding when analyzing the highest scoring
genes from the secondary screen was the presence of several
members of the cohesin complex. The cohesin complex con-
sists of five subunits (STAG1, STAG2, RAD21, SMC1A, and
SMC3) (Gruber et al., 2003; Nasmyth and Haering, 2009), and
we identified no fewer than four of these (STAG1, STAG2,
RAD21, and SMC3) among our top 20 genes, strongly pointing
toward a crucial function of the cohesin complex in regulation
of HSCs (Figure 2E). Moreover, recent large-scale sequencing
studies have identified recurrent mutations in the cohesin
genes in myeloid malignancies, also suggesting a functional
role of these genes in hematopoiesis (Kon et al., 2013; Pa-
paemmanuil et al., 2013; Welch et al., 2012). We therefore
decided to focus our further analysis on these genes and deter-
mine in higher detail the functional role of the cohesin complex
in human HSCs.
Knockdown of Cohesin Genes Restricts Differentiation
and Expands Primitive Cells In Vitro
To investigate the role of cohesin in human hematopoiesis, we
first analyzed the expression pattern of the four cohesin genes
identified in our screen in subsets of hematopoietic cells ranging
from HSCs to committed progenitors, as well as more differenti-
ated cells (Figures S2A and S3A). Overall, we found that the co-
hesin genes were robustly and widely expressed across all these
subsets and did not appear to be preferentially expressed in any
of the populations (Figures S2B and S3B). STAG2 and RAD21
showed around 2-fold higher expression compared to STAG1
and SMC3 for most of the cell types.Figure 2. A Targeted Screen in Highly Enriched HSC Populations Id
Differentiation
(A) Ranking of the top genes from the primary screen. The highest scoring fractio
(B) Overview of the experimental outline for the targeted secondary shRNA screen
and transduced with the pooled targeted library consisting of shRNAs for the highe
their CD34 and CD90 expression were sorted and subjected to sequencing to d
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See also Tables S2 and S3.
2992 Cell Reports 14, 2988–3000, March 29, 2016 ª2016 The AuthorNext, we assayed the knockdown efficiency of each shRNA
vector targeting the cohesin genes. All the shRNAs that had
been picked out of the screen-exhibited knockdown of their
respective genes in human CD34+ cells (Figure 3A), and the level
of knockdown correlated well with the degree of enrichment ex-
hibited in the screen (data not shown). We then functionally vali-
dated each lentiviral shRNA vector in individual experiments in
CD34+-sorted cells to ascertain whether the observed enrich-
ment of the cohesin complex members was a true positive hit.
For this purpose we used a vector expressing GFP (Figure S4A)
to be able to track the transduced cells during culture. CD34+-
sorted cells were transduced with either a control (scrambled
shRNA) vector or shRNAs targeting each of the cohesin genes
(two shRNAs each for RAD21 and SMC3 and three shRNAs
each for STAG1 and STAG2). The transduced cells were cultured
in serum-free medium supplemented with growth factors and
analyzed by flow cytometry every week during 4 weeks to deter-
mine the expression levels of CD34 and CD90 in the GFP-posi-
tive cells (Figure 3B). During the 4-week culture period, all
shRNAs showed an increased expansion of both total CD34+
cells (Figure S4B) and the HSC-enriched CD34+CD90+ popula-
tion (Figures 3B and 3C) compared to controls. Knockdown of
STAG2, in particular, showed a clear correlation between knock-
down levels and expansion of the CD34+CD90+ population, but
also knockdown of SMC3 and RAD21 displayed a dose-depen-
dent phenotype. Taken together, this shows that reduced
expression of cohesin genes preserves the immature state of hu-
man HSPCs in culture.
Cohesin-Deficient HSCs Show Delayed Differentiation
but Overall Increased Reconstitution Potential following
Transplantation to Primary and Secondary
Immunodeficient Mice
Given the profound effects executed by cohesin knockdown in
cultured humanHSPCs, we next wanted to assess the role of co-
hesin in a physiological context in vivo. This would further allow
us to more accurately evaluate any HSC-specific outcomes.
Since STAG2 knockdown had shown the strongest effect on
the CD34+CD90+ population across all three shRNAs and was
the highest scoring cohesin gene from the screen, we decided
to initially focus on this gene when evaluating effects of cohesin
knockdown in vivo. Cord blood-derived CD34+CD38CD90+
CD45RA cells were transduced with lentiviral shRNA vectors
(shSTAG2 and scrambled control), sorted for GFP expression
shortly after transduction (36 hr), and transplanted into suble-
thally irradiated NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice
(Figure 4A). When the mice were first analyzed for humanentifies Cohesin Genes as Candidate Regulators of Renewal and
n of genes selected for the secondary screen is marked in red.
. Cells highly enriched for humanHSCs (CD34+3890+45RA cells) were sorted
st scoring genes. After 10 days of culture, three different populations based on
etermine the shRNA distribution.
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Figure 3. Knockdown of Cohesin Genes Impairs Differentiation and Expands Primitive Cells Ex Vivo
CD34+ cells were transduced with shRNAs targeting RAD21, STAG2, SMC3, and STAG1 using 2 or 3 shRNAs per gene. Transduced cells were analyzed for the
level knockdown and functionally assayed in in vitro expansion cultures.
(A) Knockdown efficiency of shRNAs targeting cohesin genes as measured by qPCR. Error bars represent SD.
(B) Overview of the in vitro expansion assay and representative fluorescence-activated cell sorting (FACS) plots showing CD34 and CD90 expression after
2 weeks of culture.
(C) Expansion of the CD34+CD90+ cell number over a period of 4 weeks for all tested cohesin genes compared to controls. Error bars represent SD.
See also Figures S2–S4.chimerism in peripheral blood (PB) after 8 weeks, we observed
significantly lower engraftment levels for the STAG2 knockdown
cells compared to controls, while at 16 weeks post-transplanta-
tion the engraftment levels were more or less equal in PB (Fig-
ure 4B). However, strikingly, when examining the bone marrowCell(BM) after 16 weeks, there was amore than 2-fold increase in hu-
man cells in the STAG2-deficient group (Figure 4B). This indi-
cates a delayed differentiation of STAG2-deficient HSPCs in vivo
with a relative expansion of immature cells over time. When
analyzing the BM-engrafted human cells in more detail, weReports 14, 2988–3000, March 29, 2016 ª2016 The Authors 2993
observed a myeloid skewing as determined by an increased
fraction of CD33/15-positive cells for the STAG2-targeted cells
(Figure 4C). Moreover these long-term engrafted cells displayed
a significantly increased frequency of the HSC-enriched
CD34+CD38 population (Figure 4C), indicating an expansion
at the level of HSCs aswell. This increase of HSC numbers in vivo
was functionally confirmed in secondary transplantation experi-
ments in which the STAG2-deficient group, but not the control
group, showed robust human engraftment levels (Figure 4D).
To verify that the observed in vivo phenotype was specifically
associated with STAG2 knockdown but also relevant for other
cohesin components, we performed similar transplantation
experiment with an additional shRNA targeting STAG2, as well
as two independent shRNAs targeting SMC3. Indeed, cells tar-
geted by these other shRNAs showed significantly higher levels
of human chimerism in the bone marrow of long-term engrafted
animals (Figure 4E). The enhanced engraftment capability of
cohesion-deficient HSCs was further strengthened in secondary
transplants for shSMC3-transduced cells (Figure S5C). How-
ever, there were some notable differences between STAG2-
and SMC3-targeted cells in terms of engraftment kinetics and
differentiation patterns. First, engraftment levels in peripheral
blood were higher in SMC3-targeted cells at 16 weeks, indi-
cating a less severe impact on differentiation (Figure S5A). More-
over, both shRNAs for STAG2 triggered a pronounced myeloid
skewing, while the two SMC3 shRNAs showed a normal
myeloid/lymphoid distribution compared to control (Figure S5B).
These differences in differentiation potential could either be due
to distinct functions of SMC3 and STAG2, respectively, or a
dosage effect at the level of the entire cohesin complex, where
their respective knockdown from these particular shRNAs im-
pairs the complex to a different extent.
Overall, our findings in vivo indicate a maturation block in
cohesion-deficient HSCs resulting in delayed differentiation
coupled with enhanced renewal and reconstitution potential.
Several of the observed effects include features that are associ-
ated with myeloid neoplasms. However, we did not observe any
signs of malignant disease in either primary or secondary trans-
planted mice for any of the STAG2/SMC3 shRNAs, indicating
that cohesin deficiency alone may not be sufficient to trigger
leukemia.
Silencing of Cohesin Genes Results in Immediate
Transcriptional Changes with a Shift toward a More
HSC-like Gene Expression Signature
The ring-like structure formed by the cohesin complex functions
to hold chromatin strands together and was originally identified
as a regulator of proper sister chromatid segregation during
mitosis. Other functions of cohesin have recently been
described, including control of DNA damage repair, as well as
regulation of gene expression through mediation of long-range
DNA interactions and accessibility to gene regulatory elements
(Panigrahi and Pati, 2012).
To gain a basic understanding of the mechanisms behind the
observed effects from cohesin knockdown, we performed tran-
scriptome analysis of cohesin deficient cells. CD34+ cells were
transduced with shRNAs targeting each of the four cohesin
genes in five independent replicates, and 36 hr later the cells2994 Cell Reports 14, 2988–3000, March 29, 2016 ª2016 The Authorwere harvested and subjected to global gene expression
profiling using microarrays (Figure 5A). We decided to minimize
the time between transduction and transcriptome analysis in or-
der to assess the immediate transcriptional changes triggered by
cohesin knockdown independent of any secondary effects. Hier-
archical clustering by Pearson correlation showed that all 20 co-
hesin knockdown samples clustered tightly together and were
distinctly separated from three independent groups of control
samples (Figure 5B). Next, we matched our expression dataset
to a gene set specific for cord blood-derived HSCs (Laurenti
et al., 2013) using gene set enrichment analysis (GSEA) software
(Subramanian et al., 2005), and found that upregulated genes
had a strong enrichment of HSC-specific genes, both when
analyzing the knockdown of individual cohesin components (Fig-
ure S6A) and when analyzing all the components together (Fig-
ure 5C). The leading edge genes from this analysis are listed in
Table S4. To validate the microarray data, we selected the top
two genes of the HSC-specific leading edge (CRHBP and
MYCT1) and two additional genes with a more established role
in human HSCs (SOCS2 and KLF5) and performed expression
analysis by qPCR (Vitali et al., 2015; Taniguchi Ishikawa et al.,
2013). We found the qPCR results to be similar to the microarray
data (Figure S6B). Gene sets associated with cell cycle and
apoptosis did not show any enrichment among the differentially
expressed genes, suggesting that the immediate molecular con-
sequences of cohesin deficiency are associated with a pre-
served immature state of the HSPCs rather than a proliferative
response (Figure S6A). Our findings support a model in which
the functional outcome of cohesin knockdown in HSPCs is trig-
gered directly through alterations in its ability to control accessi-
bility to transcriptional regulators, rather than secondary genetic
events triggered by, for example, genomic instability from
impaired sister chromatid separation or deficient DNA repair
mechanisms.
DISCUSSION
We report here on the successful development of a genome-
wide RNAi screening approach targeted to primary human he-
matopoietic stem and progenitor cells to define genes and
pathways associated with self-renewal and differentiation.
Based on findings from the screen, we implicate the cohesin
complex as a crucial regulator of cell-fate decisions influencing
self- renewal and differentiation in HSCs both in vitro and in vivo.
These efforts represent a genome-wide RNAi screen targeted
to primary human HSPCs. The main limiting factor when per-
forming functional screens in primary human cells is cell number.
This obviously becomes even more challenging when rare cell
subsets, such as stem and progenitor cells, are studied. Through
unique access to cord blood with daily deliveries from several
local hospitals, we were able to gather the necessary quantities
to perform a screen in enriched primary HSPCs with reasonable
coverage (300X). Overall, for the primary and secondary screens
performed here, we isolated cells frommore than 150 cord blood
units. Despite access to these large quantities of cord blood, we
reasoned that a screen in the most enriched HSC fraction would
not yield sufficient coverage for a genome-wide library.
We therefore used the assumption that pre-selecting geness
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influencing expansion in a broader population of HSPCs through
a primary near genome-wide screen and then subsequently nar-
rowing down potential candidates in a secondary screen using a
more stringent assay and a better defined HSC target population
(CD34+CD38CD90+CD45RA cells) would allow us to identify
genes specifically influencing HSC-fate options associated
with self-renewal and differentiation, independent of any general
effects on proliferation. It is clear from our further analysis of the
cohesin genes that the approach successfully selected for rele-
vant outcomes in that respect. Importantly, this two-step para-
digm to globally screen for modifiers of HSC fate and many of
the principles used for analysis are not limited to RNAi libraries
but can be employed in a similar way with, e.g., CRISPR/Cas
systems delivered through lentiviral vectors.
One of the biggest challenges when performing large-scale
RNAi screens is to avoid false-positive hits triggered by off-target
activity or, when using lentiviral delivery, positional effects from
vector integration. These challenges were possible to address
to some extent by ensuring that multiple shRNAs targeting a
certain gene were identified and scored across many transduc-
tion replicates in the screen. Moreover, we added stringent pa-
rameters based on documented knockdown efficiency of the
shRNAs, as well as relevant gene expression within the hemato-
poietic system to enhance the specificity and further avoid false-
positive hits. Finally, we considered the expansion phenotype to
be less influenced by aberrant toxicity or off-target activity
compared to depletion events and therefore focused our anal-
ysis on the identification of negative regulators from the enriched
fraction of shRNAs. These efforts of excluding false-positive re-
sults have inevitably filtered out a number of ‘‘true’’ hits, and the
screen should therefore, for these reasons, not be regarded as a
comprehensive assessment of all genes in the library. Neverthe-
less, our findings suggest that we were able to broadly define
relevant candidates, both in terms of general expansion of
CD34+ cells and, more specifically, as mediators of self-renewal
and differentiation in HSCs. The data from the screens presented
here should therefore be a useful resource, providing candidate
regulators of primary human HSPCs. As such our data may
become useful to identify targets for ex vivo HSC expansion in
cell-therapy applications, but also to better understand the mo-
lecular and genetic basis underlying malignant hematopoiesis.
Our first analysis of the primary screen showed a strong
enrichment of cancer-related genes among the broadly defined
candidate genes. This was a quite expected finding given that
the selection was based on expansion of undifferentiated cells.
The cohesin complex is also highly associated with cancer and
during the last couple of years several studies have pointed to
perturbed functions of cohesin in hematological malignancies.
The prevalence of mutations in cohesin genes has been particu-
larly striking, in acute myeloid leukemia (AML), where 12% of pa-(C) Myeloid and lymphoid engraftment measured by expression of CD15/CD33 a
wasmeasured in bonemarrow 16weeks after transplantation. Representative FAC
(D) Bonemarrow cells from engraftedmice were transplanted to secondary recipie
for shSTAG2 and control transduced cells.
(E) Human chimerism in the bone marrow 16 weeks after primary transplantation
shRNAs targeting SMC3. * p < 0.05, ** p < 0.01, *** p < 0.001.
See also Figure S5.
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as in myelodysplastic syndrome (MDS), where one study reports
mutations in as many as 15% of patients (Leeke et al., 2014).
Genome sequencing studies have revealed three particular
characteristics about mutations in cohesin genes in AML and
MDS patients, all of which can be reflected in our functional
studies of cohesin deficiency in normal hematopoietic precur-
sors. First, the mutations are often of inactivating character
with a high allelic frequency, suggesting a tumor-suppressor
function for cohesin with mutations acting as an early driver of
events during leukemogenesis. Our functional studies showing
increased renewal and impaired differentiation of HSPCs upon
cohesin deficiency clearly support a strong tumor-suppressor
role for cohesin. Second, cohesinmutations affect all genemem-
bers of the complex but do not co-occur suggesting that they are
mutually exclusive (Welch et al., 2012). Our findings support this
notion, as targeting several of the cohesin genes independently
resulted in similar functional outcomes. Third, cohesin mutations
are associated with an intact karyotype of the malignant cells,
speaking against perturbation of the classical function of cohesin
in regulating sister chromatid segregation as a major cause of
malignant development. Rather, it has been suggested that the
more recently defined role of cohesin in regulation of gene
expression bymediating DNA accessibility to gene regulatory el-
ements would be important in this context (Kagey et al., 2010).
Our results provide support for this as cohesin knockdown trig-
gered immediate transcriptional changes (upregulation of HSC
specific genes) that could be linked to the functional outcome.
These correlations between our cohesin-deficient HSPCs and
hematopoietic malignancies with cohesin mutations illustrate
the power of RNAi for functional modeling of haploinsufficient
tumor suppressor genes whose incomplete loss of expression
accelerates tumor development. A complete gene knockout
strategy is not feasible in this context. For example, a complete
disruption of cohesin is detrimental to cell survival and function
(Rollins et al., 2004; Vass et al., 2003) and would not allow the
identification of its role as a tumor suppressor. Haploinsufficient
tumor suppressor genes are further particularly challenging to
identify using standard genomic approaches as they can be
affected by large heterozygous deletions that encompass
many genes. Our identification of the cohesin genes illustrate
how global RNAi screens in human HSPCs can complement
genome sequencing approaches for the identification of func-
tionally relevant tumor suppressor genes in hematopoietic
malignancies.
While this paper was being prepared for submission, three
other studies were published that reported on the functional
role of cohesin in both murine and human hematopoiesis (Ma-
zumbar et al., 2015; Mullenders et al., 2015; Viny et al., 2015).
Two of these reports investigated mouse hematopoiesis usingnd CD19, respectively, as well as levels of HSC engraftment (CD34+38 cells)
S plots gated on huCD45-positive cells, and the accumulated data are shown.
nt mice, and levels of human engraftment weremeasured again after 16 weeks
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Figure 5. Silencing of Cohesin Genes Results in Immediate Transcriptional Changes with a Shift toward a More HSC-like Gene Expression
Signature
(A) Outline of the transcriptional profiling experiment. CD34+ cells were transduced with shRNAs targeting several cohesin genes, and transduced cells were
subjected to transcriptome analysis on microarrays 36 hr after transduction.
(B) The data were subjected to unsupervised hierarchical clustering as illustrated in the Pearson correlation dendrogram.
(C) Gene set enrichment analysis (GSEA) to identify gene sets enriched in cohesin knockdown cells compared to controls. Plots using a gene set specific for HSCs
(left), cell-cycle genes (middle), and apoptosis genes (right) are shown.
See also Figure S6 and Table S4.
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either heterozygous knockout mice for SMC3 (Viny et al., 2015)
or shRNA knockdown for all the cohesin genes (Mullenders
et al., 2015), and one study was performed in human cells by
introducing mutant forms of the cohesin genes in CD34+ cells
to perturb the function of the complex (Mazumbar et al., 2015).
Overall, the findings from these studies, as well as those from
us, are remarkably consistent, given the profoundly different
strategies used to perturb cohesin and the fact the studies
have been performed in two different species. Nevertheless, all
four reports convey a common theme of preservation of the
immature phenotype of HSPCs, delayed or impaired differentia-
tion potential, in many cases coupled with a skewing toward the
myeloid lineage, as well as deregulated gene expression pat-
terns commonly associated with a preserved HSC phenotype
and reduced activation of lineage-specific gene programs. In
our study, SMC3 knockdown cells showed increased engraft-
ment levels in vivo, but in contrast to STAG2 knockdown, they
did not display amarked differentiation block ormyeloid skewing
in vivo, despite a clear increase in undifferentiated cells in vitro.
This was consistent for both SMC3 shRNAs tested and could
indicate distinct roles for the different cohesin genes in regulation
of HSPCs. However, the study by Viny et al. (2015) showed that
transplantation of bone marrow from Smc3 heterozygous
knockout mice resulted in enhanced engraftment levels with a
myeloid bias, consistent with our finding for STAG2, as well as
the observations for RAD21 and Smc1a from the studies by Ma-
zumbar et al. (2015) and Mullenders et al. (2015). This, together
with the tightly clustered expression profiles upon knockdown
of the cohesin genes, would argue against distinct roles of the
different genes in the context of HSPC function. On the other
hand, individual cohesin components may be differentially
required within the complex, and their perturbation may there-
fore disrupt cohesin function to different extents. This is sup-
ported by the varying prevalence of mutations for the cohesin
genes in myeloid neoplasms, with STAG2 and RAD21mutations
being most common. It is possible that the SMC3 knockdown in
our setting was not sufficient to induce myeloid skewing in the
NSG transplantation model, which is heavily biased toward
lymphoid reconstitution from human cells and normally shows
very low levels of myeloid cells.
Taken together, these four recent studies strongly point to-
ward a highly specific and dominant role of cohesin in regulating
cell-fate decisions in HSCs. Moreover, they provide a solid
functional basis to understand the involvement of cohesion
deficiency in myeloid malignancies. Mechanistically, all these
studies point toward alterations in cis-regulatory chromatin ar-
chitecture affecting gene transcription as the primary driver of
the cohesin-deficient phenotypes. However, the precise details
of how this occurs and which genes that may be critical targets
in the context of HSC function remains to be defined. Our gene
expression profiling identified a number of HSC-associated
genes, several of which have defined functions in HSC regula-
tion, such as ERG, EGR1, KLF5, and SOCS2, and it is possible
that one or more of these could be mediating the phenotype
observed upon cohesin disruption (Knudsen et al., 2015; Min
et al., 2008; Vitali et al., 2015; Taniguchi Ishikawa et al., 2013).
Overall, it is indeed an intriguing concept for further exploration
that perturbations in a generic complex like cohesin, with essen-2998 Cell Reports 14, 2988–3000, March 29, 2016 ª2016 The Authortial functions in all dividing cells, can result in the activation of
coordinated gene programs in stem cells.
EXPERIMENTAL PROCEDURES
Primary Human Samples
Human cord blood (CB) samples were obtained from the maternity wards of
Helsingborg General Hospital and Ska˚ne University Hospital in Lund and
Malmo¨, Sweden, after informed, written consent according to guidelines
approved by the regional ethical committee. Samples were only collected
from uncomplicated births, and no samples older than 24 hr were used. Mono-
nuclear cells were separated through density-gradient centrifugation (Lym-
phoprep, #1019818A, Medinor). CD34+ cells were magnetically isolated
(#189-046703, Fisher Scientific).
Primary Screen
CD34+ cells were lentivirally transduced with a pooled, genome-wide shRNA
library (#SHPH01, Sigma-Aldrich) as previously described (Baudet et al.,
2012) and subsequently passaged in serum-free expansion medium (SFEM,
Stem Cell Technologies), supplemented with stem cell factor (SCF), thrombo-
poietin (TPO), and FLT3-ligand (FLT3L) at 100 ng/ml from Peprotech (hereafter
abbreviated as STF). Genomic DNA from cells was collected at day 3 and at
day 20 after magnetic CD34 enrichment and isolated with the High Pure
PCR Template Preparation Kit (#11796828001, Roche Diagnostics). Provirus
integration sites were PCR amplified in 5% DMSO with 1 M Betaine (Fig-
ure S1C) and sequenced on the Illumina Genome Analyzer II.
Gene Ontology and KEGG Pathway Analysis
To identify genes from the primary screen for preliminary analysis, shRNAs
represented in less than three replicates were removed. Each shRNA was
then scored based on itsmean enrichment value across all replicates in the pri-
mary screen. Genes with at least two shRNA among the top 10% were
selected. Gene ontology analysis was conducted using the Panther overrepre-
sentation test with Bonferroni correction with a cutoff of p < 0.05. KEGG anal-
ysis was used to study pathways, using same settings as for gene ontology.
Secondary Screen
350 shRNAs targeting the highest scoring 150 genes were used to transduce
sorted CD34+3890+45RA cells. 10 days after culture, cells were stained for
CD34 and CD90 and sorted for three distinct populations: CD34+CD90+,
CD34+CD90, and CD34CD90. Cells were processed as described above.
Lentiviral Production
Lentiviruses were produced in the human 293T cell line as previously
described (Ali et al., 2009).
Gene Expression
Levels of gene expression and knockdown were ascertained with qPCR
probes from Taqman, Life Technologies: HPRT1 (Hs02800695_m1), (STAG2
(Hs00198227_m1), RAD21 (Hs00366721_mH), SMC3 (Hs00271322_m1),
STAG1 (Hs00195307_m1), MYCT1 (Hs00228305_m1), CRHBP
(Hs00181810_m1), SOCS2 (Hs00919620_m1), KLF5 (Hs00156145_m1).
36 hr post-transduction, sorted GFP+ cells were processed using the manu-
facturer’s instructions (RNeasy #74004, QIAGEN). Superscript III
(#18080085, Life Technologies) was used for reverse transcription. mRNA
levels were normalized to HPRT.
In Vitro Culture
Transduced CB-derived CD34+ cells were cultured in in SFEM/STF and
stained in PBS/2% fetal calf serum (FCS) for CD34 and CD90 expression every
week. Viability stain was done with 7-Aminoactinomycin D, (Sigma-Aldrich,
#A-9400).
Human Engraftment Assay
Sorted CD34+3890+45RA cells at the equivalent of 50,000 transduced
CD34+ cells were intravenously injected into the tail vein of sublethally (3 Gy)s
irradiated NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Human chimerism
was assayed in the peripheral blood (tail vein sampling) after 8 weeks and
fromperipheral blood, bonemarrow (left and right tibia, femur, and iliac bones),
and spleen after 16weeks. All animal experiments were approved by the Lund/
Malmo¨ Ethical Committee for Animal Research.
Microarray Analysis
Transduced CB-derived CD34+ cells were cultured in in SFEM/STF for 36 hr.
GFP+ cells were sorted and analyzed using the Human Genome U133+ array.
For details, please see the Supplemental Experimental Procedures.
Statistical Analysis
Statistical significance was calculated in GraphPad Prism (v.6.0) using paired
Student’s t test. Error bars represent SD unless indicated otherwise.
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